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Abstract
Background: Despite adequate treatment with antipsychotics, a substantial number of patients with schizophrenia 
demonstrate only suboptimal clinical outcome. To overcome this challenge, various psychopharmacological combination 
strategies have been used, including antidepressants added to antipsychotics.
Methods: To analyze the efficacy of add-on antidepressants for the treatment of negative, positive, cognitive, depressive, 
and antipsychotic-induced extrapyramidal symptoms in schizophrenia, published randomized controlled trials assessing 
the efficacy of adjunctive antidepressants in schizophrenia were reviewed using the following parameters: baseline clinical 
characteristics and number of patients, their on-going antipsychotic treatment, dosage of the add-on antidepressants, 
duration of the trial, efficacy measures, and outcomes.
Results: There were 36 randomized controlled trials reported in 41 journal publications (n = 1582). The antidepressants used 
were the selective serotonin reuptake inhibitors, duloxetine, imipramine, mianserin, mirtazapine, nefazodone, reboxetin, 
trazodone, and bupropion. Mirtazapine and mianserin showed somewhat consistent efficacy for negative symptoms and 
both seemed to enhance neurocognition. Trazodone and nefazodone appeared to improve the antipsychotics-induced 
extrapyramidal symptoms. Imipramine and duloxetine tended to improve depressive symptoms. No clear evidence supporting 
selective serotonin reuptake inhibitors’ efficacy on any clinical domain of schizophrenia was found. Add-on antidepressants 
did not worsen psychosis.
Conclusions: Despite a substantial number of randomized controlled trials, the overall efficacy of add-on antidepressants in 
schizophrenia remains uncertain mainly due to methodological issues. Some differences in efficacy on several schizophrenia 
domains seem, however, to exist and to vary by the antidepressant subgroups—plausibly due to differences in the mechanisms 
of action. Antidepressants may not worsen the course of psychosis. Better designed, larger, and longer randomized controlled 
trials are needed.
Keywords: antidepressants, antipsychotics, schizophrenia, add-on treatment
Introduction
It is well established that antipsychotics are effective in the 
majority of patients with schizophrenia (Leucht et  al., 2011). 
However, from one-fifth to one-third of the overall number of 
subjects undergoing the treatment demonstrate only partial, 
if any, improvement despite the antipsychotic treatment, ade-
quate in terms of dosage and duration (Pantelis and Lambert, 
2003). Treatment of these patients remains a major challenge, 
causing a serious burden for patients and their families and 
incurring high public health costs (Jablenski, 2000).
Clozapine, the prototypic “atypical” antipsychotic (pres-
ently referred to most often as second-generation antipsychotic 
[SGA]), is proven to be effective in a significant proportion of the 
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patients who do not respond to other antipsychotic medications 
(Kane et  al., 1998; Asenjo-Lobos et  al., 2010; Kane and Correll, 
2010). The mechanisms of the superior efficacy of clozapine are 
still obscure and are usually attributed to the drug’s complex 
receptor profile (Meltzer, 2012). However, some serious, some-
times life-threatening, adverse effects of clozapine (eg, weight 
gain, epileptic seizures, ileus, or agranulocytosis) limit its use 
in clinical practice (Kane et al., 1998). This calls for the search 
of new treatment strategies, including psychopharmacological 
approaches.
Indeed, a number of medications have been studied as 
adjuncts to antipsychotics with a goal to improve positive, nega-
tive, affective, or cognitive symptoms of schizophrenia resist-
ant to antipsychotic medication alone. These pharmacological 
agents include lithium, anticonvulsants, antiinflammatory and 
glutamatergic drugs, sex hormones, cholinesterase and phos-
phodiesterase inhibitors, and various antidepressants (Singh 
et al., 2010; Leucht et al., 2011; Vernon et al., 2014).
Although the use of antidepressants added to antipsychot-
ics in schizophrenia has been a subject of intensive research 
during the recent decades, the evidence regarding their efficacy 
still remains conflicting (Hinkelmann et al., 2013). Nevertheless, 
antidepressants tend to be routinely used by clinicians (Zink 
et al., 2010; Himelhoch et al., 2012). For instance, in the Clinical 
Trials of Intervention Effectiveness study, about one-third of 
the participants were receiving an antidepressant at the study 
baseline (Chakos et al., 2006). Thus, there seems to exist a gap 
between the wide use of antidepressants in clinical practice and 
the research evidence supporting this approach.
The present study aimed to review the published rand-
omized controlled trials (RCTs) with antidepressants added to 
antipsychotics in the treatment of schizophrenia.
Methods
Published RCTs assessing the efficacy of adjunctive antide-
pressants in schizophrenia were searched for in the PUBMED, 
PsycINFO, and PsycLIT databases from January 1960 to December 
2013, using the following keywords: “schizophrenia” AND “anti-
depressant” OR “tricyclic antidepressant” OR “monoaminoxi-
dase inhibitor” OR “selective serotonin reuptake inhibitor” OR 
“norepinephrine reuptake inhibitor”, as well as “schizophrenia” 
AND “amitriptyline” OR “imipramine” OR “clomipramine” OR 
“fluoxetine” OR “fluvoxamine” OR “sertraline” OR “paroxetine” 
OR “citalopram” OR “escitalopram” OR “venlafaxine” OR “dulox-
etine” OR “bupropion” OR “milnacipran” OR “reboxetine” OR 
“trazodone” OR “nefazodon” OR “mianserin” OR “mirtazapine” 
OR “vortioxetine” OR “vilazodone” OR “agomelatine”, as well as 
“schizophrenia” AND “double-blind” AND “augmentation”, as 
well as “schizophrenia” AND “double-blind” AND “adjunctive.” 
To obtain further data, hand searches of references in published 
review articles as well as cross-referencing were used.
All citations were reviewed using the following parameters: 
baseline clinical characteristics of patients and their antipsy-
chotic treatment, dose of the add-on antidepressant, duration 
of the trial, number of participants, efficacy measures, and 
outcome.
Results
We were able to locate a total of 36 RCTs (reported in 41 journal 
publications) including 1582 subjects with a diagnosis of schizo-
phrenia or schizoaffective disorder (Table 1). All included trials 
employed head-to-head, parallel group, double-blind design 
comparing the efficacy of an add-on antidepressant vs add-on 
placebo with the exception of trials by Friedman et al. (2005) and 
Stryjer et al. (2010) that employed a crossover design. The vast 
majority of trials were small with the number of subjects rang-
ing from 14 to 53. This number was exceeded only in the trial 
by Salokangas and coauthors (1996) (n = 90). The duration of the 
trials ranged from 1 to 24 weeks. In 18 trials, an antidepressant 
was added to first-generation antipsychotics (FGAs), in 11 trials 
to SGAs, and in the rest of the trials to various antipsychotics.
In all trials, the efficacy measures—Brief Psychiatric Rating 
Scale, Positive and Negative Syndrome Scale (PANSS), Scale 
for the Assessment of Negative Symptoms, Scale for the 
Assessment of Positive Symptoms, Clinical Global Impression 
Scale, and the Wing’s scale—were used prospectively from 
baseline to endpoint. In only 14 studies were a priori defined 
minimum cut-off points on the Brief Psychiatric Rating Scale or 
PANSS scales used as an inclusion criterion, while in the others 
the subjects were vaguely defined to be “symptomatic” or “suf-
fering from positive or negative symptoms” despite adequate 
antipsychotic treatment. Twenty-two trials included clinically 
stable subjects. Furthermore, in 21 trials, a thoroughly defined 
period of an unchanged antipsychotic treatment was required 
prior to participation in the study. This period varied from 1 
week to 6 months. Presence of the current significant depres-
sive symptoms served as an exclusion criterion in 12 trials. Of 
the others, 15 trials used depression rating scales as an outcome 
measure: the Hamilton Rating Scale for Depression, Calgary 
Depression Scale for Schizophrenia, Beck Depression Inventory, 
or Montgomery–Åsberg Depression Rating Scale. Extrapyramidal 
symptom rating scales—the Simpson-Angus Scale for extrapy-
ramidal effects, the Abnormal Involuntary Movements Scale, and 
the Barnes Akathisia Scale—were used in 17 trials. Noteworthy, 
5 trials were initially designed to investigate the effect of anti-
depressant add-on treatment of antipsychotic-induced weight 
gain (Poyurovski et  al., 2002; Bustillo et  al., 2003; Poyurovski 
et al., 2003a) or smoking cessation (Evins et al., 2005a; Weiner 
et  al., 2012). These trials also utilized psychopathology rating 
scales (PANSS, Scale for the Assessment of Negative Symptoms, 
Scale for the Assessment of Positive Symptoms, Hamilton Rating 
Scale for Depression) and were thus included into this review.
The add-on antidepressant and add-on placebo groups did 
not generally differ significantly in baseline clinical character-
istics. In only one trial (Joffe et al., 2009) the add-on antidepres-
sant group had somewhat higher PANSS total scores at baseline.
Add-On Antidepressants in the Treatment of Positive 
and Negative Symptoms of Schizophrenia
The included RCTs are presented in Table 1. In regard to the nega-
tive symptoms, trials with the tricyclic antidepressants (TCAs) 
yielded mainly positive results, but the studies were relatively 
old (Collins and Dundas, 1967; Waehrens and Gerlach, 1980; 
Siris et al., 1991). The outcomes of the SSRI trials as a group were 
controversial. Of 6 studies with fluoxetine, only 2 were positive 
(Spina et al., 1994; Goff et al., 1995). While both studies with flu-
voxamine (Silver and Nassar, 1992; Silver et al., 2000) and the only 
study with paroxetine (Jockers-Scherubl et al., 2005) were positive, 
adjunctive citalopram (Salokangas et  al., 1996; Friedman et  al., 
2005), escitalopram (Iancu et al., 2010), and sertraline (Lee et al., 
1998; Mulholland et al., 2003) failed to demonstrate any benefits 
in any of the published trials. Likewise, both trials with the selec-
tive noradrenaline reuptake inhibitor reboxetine were negative 
(Schutz and Berk, 2001; Poyurovsky, 2003a). Conversely, in the only 
trial with the selective serotonin and noradrenaline reuptake 
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inhibitor duloxetine, the active medication outperformed placebo 
on the PANSS negative subscale (Mico et al., 2011). Bupropion, a 
noradrenaline and dopamine reuptake inhibitor, demonstrated a 
trend toward improvement in negative symptoms that did not 
reach statistical significance in one RCT (Evins et al., 2005a). In 
another RCT (Weiner et  al., 2012), bupropion did not override 
placebo (for review, see Englisch et al., 2013). For mianserine, tra-
zodon, nefazodon, and mirtazapine (further referred to as recep-
tor-blocking antidepressants, since they affect serotonin 5HT2 
receptors rather than monoamine transporters, as opposed to the 
vast majority of existing antidepressants that are monoamine 
transporter blockers), most of the RCTs (8 of 12) were positive: 2 of 
3 studies with trazodone (Decina et al., 1994; Hayashi et al., 1997), 
1 of 3 studies with mianserin (Hayashi et al. 1997), and 6 of 7 stud-
ies with mirtazapine (Berk et al., 2001; Zoccali et al., 2004; Joffe 
et al., 2009; Abbasi et al., 2010; Cho et al., 2011; Caforio et al., 2013).
In only one study, an add-on antidepressant (mirtazapine) 
improved the positive symptoms of schizophrenia (Joffe et al., 
2009). Noteworthy, a trend (P = .07) in favor of an antidepressant 
was also found in 1of 3 RCTs with mianserin (Shiloh et al., 2002).
No add-on RCTs with novel antidepressants agomelatine, 
vortioxetine, or vilazodone are yet available.
Add-On Antidepressants in the Treatment of 
Depressive Symptoms of Schizophrenia
Antidepressant augmentation was found to be effective in the 
treatment of depressive symptoms of schizophrenia in only 
a small number of studies. These included imipramine (Siris 
et al., 1987), fluoxetine (Spina et al., 1994), sertraline (Mulholland 
et  al., 2003), citalopram (Zisook, 2009), reboxetine (Poyurovski 
et  al., 2003a), duloxetine (Mico et  al., 2011), and mirtazapine 
(Terevnikov et  al., 2011). The majority of the identified stud-
ies, however—3 RCTs with fluoxetine (Buchanan et  al., 1996; 
Arango et al., 2000; Bustillo et al., 2003), 2 RCTs with mirtazapine 
(Zoccali et al., 2004; Berk et al., 2009), and one RCT for each with 
paroxetine (Jockers-Scherubl et al., 2005), reboxetine (Schutz and 
Berk, 2001), mianserin (Poyurovski et al., 2003b), and trazodone 
(Stryjer et al., 2010)—generated negative results. Also both RCTs 
with bupropion (Dufresne et al., 1988; Evins et al., 2005a) were 
negative (though a desired trend was observed in the latter one. 
For review, see Englisch et al. [2013]).
Add-On Antidepressants in the Treatment of 
Extrapyramidal Side-Effects of Antipsychotics
All trials with the SSRIs (Goff et al., 1995; Lee et al., 1998; Arango 
et al., 2000; Bustillo et al., 2003; Mulholand et al., 2003; Jockers-
Scherubl et  al., 2005) demonstrated negative outcomes, as did 
both trials with reboxetine (Schutz and Berk, 2001; Poyurovksi 
et al., 2003a). Of the receptor-blocking antidepressants, mianserin 
failed to show superiority over placebo in both conducted trials 
(Hayashi et  al., 1997; Poyurovski et  al., 2003b), while both trials 
with trazodone (Hayashi et al., 1997; Stryjer et al., 2010) and the 
only trial with nefazodone (Wynchank and Berk, 2003) were posi-
tive. Mirtazapine was superior to placebo in alleviating antipsy-
chotic-induced extrapyramidal symptoms (EPS) in only 1 of the 5 
conducted trials (Joffe et al., 2009).
Add-On Antidepressants in the Treatment of 
Cognitive Dysfunction in Schizophrenia
Of the SSRIs, the only available study (one with citalopram) 
did not reveal any improvement in cognitive functions A
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(Friedman et al., 2005). Of the receptor-blocking antidepressants, 
mianserin added to FGAs showed beneficial effects on memory 
and learning with no between-group differences for executive 
functions (Poyurovski et al., 2003b). Mirtazapine outperformed 
placebo in between-group comparisons for visual-spatial ability 
and general mental speed/attentional control but not for other 
neurocognitive functions (Stenberg et al., 2010). Evins and col-
laborators (2005b) reported improvement in attention tests in an 
RCT with adjunctive bupropion, a noradrenaline and dopamine 
reuptake inhibitor.
Results
The effects of different groups of add-on antidepressants on 
major psychopathology domains of schizophrenia are sum-
marized in Table 2. The vast majority of publications reported 
no favorable effect of add-on antidepressants on the schiz-
ophrenia symptom domains. The only exception was the 
group of the receptor blocking antidepressants, with 9 studies 
reporting desirable results for negative symptoms (vs 3 stud-
ies that did not show benefits for this symptom domain) and, 
correspondingly, 2 studies (vs 1 study) for cognitive deficits.
No add-on RCTs with new novel antidepressants vortiox-
etine, vilazodone, or agomelatine could be located.
Adverse Effects Due to Adjunctive Antidepressants 
in Schizophrenia
The majority of the included studies reported overall good 
tolerability of antidepressant-antipsychotic combinations. 
Spina et al. (1994) observed, however, more common adverse 
effects in patients receiving add-on fluoxetine compared 
with those receiving an antipsychotic alone. Noteworthy, 
no RCTs reported worsened psychosis due to adjunctive 
antidepressants.
Discussion
We were able to identify 36 RCTs on combinations of antidepres-
sants with an ongoing antipsychotic treatment published in the 
period from 1968 to 2013. The RCTs comprised the majority of 
the existing antidepressants and aimed to study their efficacy 
for the main clinical domains of schizophrenia. To summarize, 
the existing evidence regarding the efficacy of antidepressants 
in the treatment of schizophrenia is mixed.
The methodological quality of the studies varied. Overall, 
the later RCTs reported more precisely than the earlier ones the 
outcome criteria, the dosages of the study drugs, the clinical 
scales used, the patient population’s clinical and demographic 
characteristics, etc. This progress of the clinical study methodol-
ogy advocates, in general, giving more weight to the most recent 
studies. Nevertheless, both old and recent RCTs have a number 
of restrictions. Almost all of them comprise small patient sam-
ples. Many publications express secondary analysis from the 
studies originally designed for negative (or sometimes also for 
overall) but not affective symptoms. This uncertainty possibly 
contributes to the heterogeneity of results obtained in different 
studies and makes a between-study comparison difficult.
Antidepressants in the Treatment of Negative 
Symptoms of Schizophrenia
Only 5 of 14 RCTs with SSRIs reported favorable results. This 
puts into question the efficacy of this antidepressant group Ta
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in the treatment of schizophrenia’s negative symptoms. From 
a theoretical viewpoint, these findings possibly indicate that 
the increase of serotonin availability in the brain per se is not 
enough to alleviate the negative symptoms.
The data on selective serotonin and noradrenaline reuptake 
inhibitor (SNRIs) are scarce. Only one small study (with dulox-
etine) is available. Its desirable result needs further validation in 
larger studies. Studies with other SNRIs are also necessary.
For the TCAs, even though 2 of the 3 existing studies were 
positive, the small number of trials and methodological issues 
(omitted report on outcome measures or use of psychiatric 
scales with questionable reliability) makes the significance of 
these results uncertain.
In both available studies with reboxetine and bupropion, 
the active drug was not more efficacious than placebo, indicat-
ing that catecholamine reuptake inhibition alone is seemingly 
insufficient to alleviate negative symptoms of schizophrenia.
Data on the receptor-blocking antidepressants are more 
convincing, since they outperformed placebo in 10 of the 13 
reported RCTs. This advantage may plausibly be interpreted 
with the dissimilar pharmacodynamic mechanisms of action of 
these compounds. While not affecting monoamine transport-
ers (and thus reuptake of monoamines), all receptor-blocking 
antidepressants inhibit the postsynaptic serotonin 5HT2 recep-
tors, a property that they share with clozapine and other SGAs 
(Meltzer, 1999). The theory of atypicality, especially popular in 
Table 2. Effects of Different Groups of Add-On Antidepressants on Major Psychopathology Domains of Schizophrenia: Summary of Randomized 
Controlled Trials (RCTs)
Antidepressant-
Group Effect Negative Symptoms Positive Symptoms
Depressive 
symptoms
Extrapyramidal 
symptoms
Cognitive 
symptoms
TCA + 1,4 (n = 101) n/a 4 (n = 14) n/a n/a
0 2 (n = 20) n/a n/a n/a n/a
SSRI + 5,7,8,15,29 (n = 187) n/a 7,21 (n = 60) n/a n/a
0 9,10,13,14,18,20,21,28,35 
(n = 335)
5,7,8,9,10,13,14,15,18,20,21,28,2 
9 (n = 489)
9,14,20,29,35
(n = 163)
8,13,14,20,21,29,35 
(n = 233)
28 (n = 19)
NRI + n/a n/a 22 n/a n/a
0 17,22 (n = 56) 17,22 (n = 56) 17 (n = 30) 17,22 (n = 56) n/a
SNRI + 38 (n = 33) n/a 38 (n = 33) n/a n/a
0 n/a 38 (n = 33) n/a n/a n/a
NDRI + n/a n/a n/a n/a 27 (n = 53)
0 26, 40 (n = 85) 26, 40 (n = 85) 3, 26 (n = 91) n/a n/a
Receptor blocking 
antidepressants
+ 6,11,12,16,19,25,31,32,36,41 
(n = 325)
31 (n = 39) 39 (n = 41) 11,24,31,34 (n = 140) 23,33 (n = 67)
0 23,30,34 (n = 83) 6,11,12,16,19,23,25,30,32,34,36 
(n=341)
19,23,25,30,34
(n = 125)
12,16,23,30,32,37
(n = 200)
n/a
Abbreviations: n/a, no published RCTs found; NDRI, noradrenaline and dopamine reuptake inhibitor; NRI, selective noradrenaline reuptake inhibitor; SNRI, serotonin 
and noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; +, result favoring antidepressant over placebo; 0, no 
difference between antidepressant and placebo.
Worsening of schizophrenia symptoms was not reported in any of the studies. The numbers in the syndrome columns refer to the index number of the RCT listed be-
low. The list is arranged in chronological order, meaning that the larger the number the more recent (and often methodologically more reliable) is the corresponding 
study. The positive (+) and negative (0) studies ratio depicts roughly the balance of pro et contra evidence for each antidepressant group in each symptom domain. 
(The studies are not weighted in terms of methodological quality or number of participants and should be thus taken with caution).
List of RCTs:
1. Collins and Dungas, 1967
2. Waehrens and Gerlach,1980
3. Dufresne et al., 1988
4. Siris et al., 1991
5. Silver and Nassar, 1992
6. Decina et al., 1994
7. Spina et al., 1994
8. Goff et al., 1995
9. Buchanan et al., 1996
10. Salokangas et al., 1996
11. Hayashi et al., 1997(a)
12. Hayashi et al., 1997(b)
13. Lee et al., 1998
14. Arango et al., 2000
15. Silver et al., 2000
16. Berk et al., 2001
17. Schutz and Berk, 2001
18. Poyurovski et al., 2002
19. Shiloh et al., 2002
20. Bustillo et al., 2003
21. Mulholand et al., 2003
22. Poyurovski et al., 2003(a)
23. Poyurovski et al., 2003(b)
24. Wynchank and Berk, 2003
25. Zoccali et al., 2004
26. Evins et al., 2005(a)
27. Evins et al., 2005(b)
28. Friedman et al., 2005
29. Jockers-Scherubl et al., 2005
30. Berk et al., 2009
31. Joffe et al., 2009
32. Abbasi et al., 2010
33. Stenberg et al., 2010
34. Stryjer et al. 2010
35. Iancu et al. 2010
36. Cho et al., 2011
37. Lee et al., 2011
38. Mico et al., 2011
39. Terevnikov et al., 2011
40. Weiner et al., 2012
41. Caforio et al., 2013
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the late 1990s, postulates that antipsychotics with higher affin-
ity to the 5HT2 than to the dopamine D2 receptors (the atypical 
antipsychotics, or SGAs) were more effective in treating positive 
and negative symptoms and cognitive deficits and less prone 
to cause extrapyramidal side-effects compared with the FGAs, 
potent dopamine D2 blockers with low or negligible 5HT2 recep-
tor inhibition (Meltzer and Massey, 2011). The rationale for the 
use of the receptor-blocking antidepressants in schizophrenia 
is the presumption that combination of an inhibitor of the 5HT2 
receptor (antidepressant) with a relatively pure D2 blocker (FGA) 
would result in a clinical effect resembling that of the SGAs, with 
possible additional benefits in terms of efficacy and tolerability 
(Berk et al., 2001; Joffe et al., 2009). Preliminary evidence for this 
presumption was gained in a study by Duinkerke and coauthors 
(1993) in which add-on ritanserin, a pure 5HT2 blocker devoid 
of antidepressive properties, improved negative symptoms in 
haloperidol-treated schizophrenia patients.
On the other hand, in 4 of 6 positive studies, mirtazapine was 
added to risperidone, clozapine, or olanzapine –each of them 
known to be a potent 5HT2A/C blocker by itself, which makes lit-
tle sense from the viewpoint of the above-mentioned atypicality 
theory. A possible explanation for this advantageous effect may 
be the affinity of mirtazapine to some other (than 5HT2) types of 
receptors. In addition to the 5HT2 receptors, mirtazapine inhib-
its the postsynaptic serotonin 5HT3 receptors and presynaptic 
noradrenaline α2 receptors and indirectly stimulates postsynaptic 
serotonin 5HT1A receptors (de Boer, 1996), all of these believed to 
be involved in the pathophysiology of schizophrenia. Antagonists 
of the 5HT3 receptors seem potentially beneficial in the treat-
ment of schizophrenia (Costall and Naylor, 1992). In a preclinical 
study by Pitsikas and Borsini (1996), a 5HT3 receptor antagonist, 
itasetron, demonstrated procognitive effects, and in a clinical 
trial by Zhang and collaborators (2006), another 5HT3 antagonist, 
ondansetron, was added to an on-going treatment with haloperi-
dol and improved negative symptoms, general psychopathology, 
and cognitive functions in patients with schizophrenia.
Blockade of the noradrenaline α2 receptors also may be use-
ful in the treatment of schizophrenia. In an RCT by Litman and 
coauthors (1996), the α2 antagonist idazoxan added to fluphena-
zine produced clinical improvement comparable with that of 
clozapine. This finding was later supported by 2 preclinical stud-
ies. Wadenberg and coauthors (2007) found idazoxan to potenti-
ate the antipsychotic-like effect of both FGA (haloperidol) and 
SGA (olanzapine) and also to reverse haloperidol-induced cat-
alepsy in the laboratory animals. In another preclinical study, 
Marcus and coauthors (2010) reported that adjunctive idazoxan 
had improved the efficacy of risperidone and facilitated cortical 
dopaminergic and glutamatergic neurotransmission.
Rummel et  al. (2005) performed a systematic review of 5 
RCTs (comprising the TCAs, receptor-blocking antidepressants, 
and SSRIs) available at that time and fulfilling the rigorous sys-
tematic review criteria. The authors concluded that “the com-
bination of antipsychotics and antidepressants may be more 
effective in treating negative symptoms of schizophrenia than 
antipsychotics alone.” This conclusion, although not differenti-
ating between effects of different antidepressant subgroups, is 
mainly in line with that of the current review.
The efficacy of add-on antidepressants on negative symp-
toms of schizophrenia was reviewed by Singh and coauthors 
(2010). Based on an analysis of 23 RCTs (n = 819), the authors 
found that add-on treatment with antidepressants was more 
effective for negative symptoms in chronic schizophrenia than 
monotherapy with antipsychotics. In particular, Singh and col-
laborators concluded that fluoxetine, trazodone, and ritanserin 
were the most efficient antidepressants for treating negative 
symptoms, while the majority of other antidepressants did not 
express such advantages compared with placebo. These findings 
seem to be controversial, especially for fluoxetine, which has 
been unable to outperform placebo in 3 of 5 studies published 
to date. Unlike Singh and coworkers (2010), we have found that 
data supporting clinical efficacy of add-on antidepressants on 
negative symptoms is most consistent for the receptor-blocking 
antidepressants. This difference in the results may be partly 
explained by the different number of studies included in these 
2 reviews (9 RCTs on receptor-blocking antidepressants in 
the review by Singh and co-authors vs 13 RCTs in the current 
review). Some of the RCTs with receptor-blocking antidepres-
sants (Abbasi et  al., 2010; Stryjer et  al., 2010; Cho et  al., 2011; 
Caforio et al., 2013) were not available at the time of preparation 
of the review by Singh and co-authors. Furthermore, the dis-
crepancy could result from different methodology employed by 
Singh and co-authors, who based their conclusions on the com-
putation of the effect size for each antidepressant separately.
Englisch and colleagues (2013) did not find in their review 
any RCT data on improved negative symptoms with adjunctive 
bupropion.
Antidepressants in the Treatment of Positive 
Symptoms of Schizophrenia
Antidepressants seem to have no desirable effect on positive 
symptoms of schizophrenia, as almost all RCTs were disap-
pointing in this respect. The only exception was a study by Joffe 
and coauthors (2009), in which mirtazapine (but not placebo) 
added to on-going therapy with various FGAs improved positive 
symptoms. This result diverged from other mirtazapine trials. 
It is possible that in that particular study, the researchers suc-
ceeded in minimizing the regression to the mean by a sound 
process of stabilization of clinical status and dosage of the FGAs. 
Also, placebo response and low adherence to the protocol proce-
dures were minimized by a placebo run-in period, which prob-
ably explained the high patient retention level. Stabilization and 
low drop-out rate might permit for surfacing a possible additive 
antipsychotic effect of mirtazapine. This observation, however, 
has to be replicated in other studies with similarly rigorous 
methodology.
In clinical practice, physicians are sometimes concerned 
with a risk of worsening or exacerbation of psychosis when 
prescribing antidepressants to patients with schizophrenia 
(Petit, 1994). Moreover, some current schizophrenia treatment 
guidelines suggest caution when using antidepressants (APA, 
2004). This review does not support this opinion, since not a 
single study with an add-on antidepressant reported worsen-
ing of positive symptoms. The majority of the presented RCTs, 
however, involved subjects with chronic schizophrenia, with 
only 3 trials comprising acutely ill subjects. It therefore remains 
unclear to what extent this observation can be extrapolated to 
acute schizophrenia.
Antidepressants in the Treatment of Depressive 
Symptoms of Schizophrenia
Only 2 of 6 studies with SSRIs were positive, and exactly the 
same proportion (2 of 6)  was found with regard to receptor-
blocking antidepressants. This puts the efficacy of both anti-
depressant groups into question. The antidepressants with 
sound noradrenaline activity may, however, be of interest 
for this symptom domain, since 1 of the 2 existing RCTs with 
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reboxetine, the only study with imipramine, and the only study 
with duloxetine (compounds with a pronounced noradrena-
line enhancing effect) reported improved depression. A  trend 
in favor of active compound over placebo was observed in 1 of 
2 RCTs with adjunctive noradrenaline and dopamine inhibitor 
bupropion. Of the 6 published trials with the receptor-blocking 
antidepressants, only one (Terevnikov et  al., 2011) reported 
improved depression with add-on mirtazapine.
To summarize, the evidence regarding the efficacy of anti-
depressants in the treatment of depression in schizophrenia is 
scarce and controversial. The main methodological issue in this 
area is that the study population was not selected specifically 
for depressive symptoms, with the only exception of the post-
psychotic depression study by Siris and co-authors (1987). In the 
rest of the studies, change in depression scores was a subject for 
a secondary analysis.
Also, Whitehead and coauthors (2012) in their Cochrane 
review concluded that, although antidepressants may be of 
some benefit for people with depression and schizophrenia, 
the evidence was still far from convincing. The authors of that 
review also emphasized poor quality of the available literature 
as a contributing factor for this uncertainty.
Antidepressants in the Treatment of Extrapyramidal 
Side-Effects of Antipsychotics
For the monoamine transporter inhibitors, only SSRIs and the 
noradrenaline reuptake inhibitor reboxetine studies were iden-
tified. All these studies were negative, probably not surprisingly 
given the lack of theoretical basis for such combination in EPS. 
Moreover, the SSRIs are reported to even cause EPS in patients 
with major depressive disorder (Govoni et al., 2001).
For the receptor-blocking antidepressants, a positive effect 
on the FGA-induced EPS was found in both studies with trazo-
done (Hayashi et al., 1997; Stryjer et al., 2010) but in neither of the 
mianserin studies (Hayashi et al., 1997; Poyurovski et al., 2003b). 
Also, 4 of 5 studies with mirtazapine (Berk et  al., 2001, 2009; 
Abbasi et al., 2010; Lee et al., 2011) were negative. Nefazodone 
was found to improve haloperidol-induced Parkinsonism but 
not akathisia or tardive dyskinesia (Wynchank and Berk, 2003).
The use of receptor-blocking antidepressants for the EPS 
arises from the theoretical assumption of dopamine insuf-
ficiency in the basal ganglia as the cause of EPS (Tatara et al., 
2012). Inhibition of the 5HT2A/C receptors—a common phar-
macological effect of SGAs and receptor-blocking antidepres-
sants—may increase availability of dopamine in this area, 
thereby alleviating EPS. Another possible mechanism of alleviat-
ing antipsychotic-induced EPS by some of the receptor-blocking 
antidepressants may be an indirect stimulation of the serotonin 
5HT1A receptors that leads to decrease of serotonin at 5HT2C 
receptors located on dopaminergic neurons (Haleem, 2006).
In sum, despite encouraging theoretical presumptions, the 
evidence regarding the efficacy of receptor-blocking antidepres-
sants for antipsychotic-induced EPS is limited and contradic-
tory. Only trazodone and nefazodone were found effective, while 
mianserin and mirtazapine were probably not. As marketing 
of nefazodone has been discontinued, the nefazodone-related 
findings are no longer relevant for clinical practice. Moreover, 
positive findings with receptor-blocking antidepressants are 
available for only FGA-induced EPS and may be extrapolated on 
the SGAs only with caution. Given that the use of FGAs has been 
markedly diminished during recent years and further decrease 
may happen in the future, the results of these studies are rather 
of theoretical than of practical interest.
Antidepressants in the Treatment of Cognitive 
Deficits Related to Schizophrenia
Neurocognitive effects of antidepressants added to antipsychot-
ics in schizophrenia have been studied in only 3 RCTs.
A serotonin reuptake inhibitor, citalopram, did not improve 
cognition in schizophrenia (Friedman et al., 2005). The increase 
of availability of serotonin alone in the brain may not therefore 
improve neurocognition.
Evins and coauthors (2005b) reported improved attention in 
patients with schizophrenia treated with bupropion for smok-
ing cessation. This positive change became significant only after 
controlling for abstinence status. The influence of nicotine use 
and smoking cessation on cognitive performance in this study 
makes the results difficult to interpret.
On the contrary, 2 receptor-blocking antidepressants with 
a similar mechanism of action, mianserin (Poyurovsky et  al., 
2003b) and mirtazapine (Stenberg et al., 2010, 2011), did improve 
neurocognition in FGA-treated schizophrenia patients.
As for the negative symptoms, the plausible proneurocog-
nitive effect of mirtazapine and mianserin in schizophrenia 
may emerge from their receptor-binding profile. First, they may 
enhance prefrontal catecholamine activity via 5HT2A or 5HT2C 
receptor blockade (as most SGAs do), thereby enhancing activ-
ity of the prefrontal cortex (Liegeois et al., 2002; Menzies, 2007). 
Second, the 5HT3 receptor modulation by mianserin or mir-
tazapine could improve neurocognition (Akhondzadeh et  al., 
2009) through increased release of acetylcholine (Passani and 
Blandina, 1998). Third, mirtazapine might improve neurocog-
nition as a result of the indirect agonism of 5HT1A receptors 
(Sumiyoshi et  al., 2007). Fourth, mianserin and mirtazapine 
inhibit the noradrenergic α2 receptors. Inhibition of the α2 recep-
tors can enhance neurocognition via noradrenaline-mediated 
modulation of response to environmental stimuli (Friedman 
et al., 2004). Furthermore, the α2 receptor antagonism seems to 
boost hippocampal neurogenesis (Rizk et al., 2006). Mirtazapine 
is an even more potent α2 antagonist than clozapine, which may 
explain its additional neurocognition-enhancing effect even if 
added to clozapine, as demonstrated in an open label trial by 
Delle Chiaie et al. (2007). Mirtazapine may also boost the levels 
of the Brain-Derived Neurotrophic Factor (Rogoz et  al. 2005), a 
major mediator of neurogenesis and neuroplasticity, which are 
often abnormal in patients with schizophrenia (Rizos et al., 2008).
Vernon and coauthors (2014) found in their meta-analysis 
clinically negligible (although statistically significant) improve-
ment of neurocognitive functions with adjuvant antidepres-
sants. However, while Vernon and colleagues analyzed pooled 
antidepressants, in the current review, each antidepressant 
study has been given separately.
The number of studies presented in both reviews was small. 
Thus, the evidence for the proneurocognitive potential of add-
on antidepressants is, so far, insufficient but deserves further 
research.
Limitations
The RCT is the gold standard of clinical efficacy studies. 
However, RCTs are fraught with patient selection bias and, thus, 
the results of available naturalistic prospective studies, mirror 
design studies, as well as pertinent register studies should be 
taken into account for balanced clinical decisions. Furthermore, 
we have not performed quantitative analyses of the data nor 
included unpublished data as it would be required for a system-
atic meta-analysis. Moreover, the vast majority of the available 
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RCTs are small and methodologically heterogenic, which calls 
for caution when interpreting our results. In a substantial part 
of the RCTs in this review, the reported outcomes were a result 
of secondary analysis.
This review has focused predominantly on the efficacy of 
adjunctive antidepressants, while in clinical practice the poten-
tial benefits should be balanced against unwanted side-effects of 
these drugs and of antidepressant-antipsychotic combinations.
Further Directions
In the future, well-designed, larger, and longer RCTs are needed. 
There is also a need for trials designed specifically for certain 
symptom domains, with appropriately selected patients and 
pertinent rating scales. Despite an existing theoretical ration-
ale, there is a lack of studies assessing the effects of bupropion, 
reboxetine, SNRIs, and reversible inhibitors of monoamine oxi-
dase A on cognitive function in schizophrenia.
The future studies should also focus on new, novel, add-on 
antidepressants that have come into clinical practice in recent 
years. Of interest may be, for instance, vortioxetine. In addition 
to the conventional inhibition of the serotonin (5HT) transporter, 
vortioxetine demonstrates an affinity to the serotonin 5HT1a, 
5HT1b, 5HT1d, 5HT3, and 5HT7 receptors. Furthermore, it modu-
lates the GABA, MNDA, noradrenergic, dopaminergic, choliner-
gic, and histaminergic neurotransmitter systems (Leiser et al., 
2015; Stahl, 2015). Some of these receptors and neurotrans-
mitters may be involved in pathophysiology of schizophrenia. 
In addition to the symptoms of depression, vortioxetine may 
improve cognitive functions in patients with major depressive 
disorder (Sole et al., 2015).
Conclusions
There exists a substantial number of RCTs on the efficacy of 
add-on antidepressants, but due to methodological issues the 
results remain uncertain. Receptor-blocking antidepressants 
mirtazapine and mianserin show somewhat consistent effica-
ciousness for negative symptoms. The evidence for EPS, neu-
rocognition, and depression domains is even more ambiguous 
and should be interpreted with caution. Some receptor-blocking 
antidepressants (trazodone and nefazodone) seem to improve 
FGA-induced EPS, while others (mirtazapine and mianserin) 
appear to enhance neurocognition. Transporter-blocking anti-
depressants with prominent noradrenergic activity tended to 
improve depressive symptoms.
The overall data for the SSRIs are rather disappointing. An 
add-on antidepressant (mirtazapine) improved positive symp-
toms in only one study. However, the data unequivocally show 
that adjunctive antidepressants do not worsen psychosis, at 
least in chronic schizophrenia. The caution recommended for 
antidepressants in some current schizophrenia treatment 
guidelines may, therefore, need reappraisal.
Interest Statement
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